Induction of anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (ab1). Relation to the clinical outcome--an important antitumoral effector function?
- PMID: 1937495
- DOI: 10.1089/hyb.1991.10.421
Induction of anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (ab1). Relation to the clinical outcome--an important antitumoral effector function?
Abstract
Forty-three patients with metastatic colorectal carcinoma (CRC) were treated with the unconjugated mouse monoclonal antibody (MAb) 17-1A (ab1) only. The presence of antiidiotypic antibodies (ab2) and anti-antiidiotypic antibodies (ab3) were analyzed using an ELISA technique and a mixed hemadsorption assay respectively. Ninety-five percent (41/43) of the patients developed ab2 both of the IgM and the IgG classes. Forty-seven percent (20/43) of the patients had detectable ab3 after therapy, two of them also before administration of MAb 17-1A. Binding in vitro of ab3 (ab1) to CRC cells could be specifically inhibited by ab1. Ab3 bound to human monoclonal antiidiotypic antibodies and to a goat antiidiotypic antibody (ab2). Both these ab2 were directed against MAb 17-1A (ab1). There was a strong correlation between the presence of ab3 and the clinical outcome. Ab3+ patients survived significantly longer than those who did not develop ab3 antibodies, 80 weeks vs 38 weeks (p less than 0.001). A statistically significant correlation was found between the presence of ab3 and the anti-tumor response (CR + PR + MR + SD) (p = 0.01). Thus, induction of an antiidiotypic cascade seems to be an important antitumor effector function of MAb in the treatment of cancer patients.
Similar articles
-
Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy?Cancer Immunol Immunother. 1993 Sep;37(4):264-70. doi: 10.1007/BF01518521. Cancer Immunol Immunother. 1993. PMID: 8348565 Free PMC article.
-
Immunomodulatory activity of monoclonal anti-idiotypic antibody to anti-colorectal carcinoma antibody CO17-1A in animals and patients.J Immunother Emphasis Tumor Immunol. 1994 May;15(4):303-11. doi: 10.1097/00002371-199405000-00009. J Immunother Emphasis Tumor Immunol. 1994. PMID: 8061902
-
A comparison of the anti-idiotypic responses generated by antibodies to a protein and a hapten: a common interspecies idiotype on antibodies against human albumin induces an idiotypic network in rabbits.Immunol Cell Biol. 1996 Feb;74(1):72-80. doi: 10.1038/icb.1996.10. Immunol Cell Biol. 1996. PMID: 8934657
-
Modulation of cancer patients' immune responses by anti-idiotypic antibodies.Int Rev Immunol. 1989;4(4):347-57. doi: 10.3109/08830188909044787. Int Rev Immunol. 1989. PMID: 2519932 Review.
-
Anti-idiotype and recombinant antigen in immunotherapy of colorectal cancer.Cell Biophys. 1994;24-25:143-53. doi: 10.1007/BF02789225. Cell Biophys. 1994. PMID: 7736518 Review.
Cited by
-
Chemotherapy and immunotherapy of colorectal cancer.Med Oncol Tumor Pharmacother. 1991;8(3):207-20. doi: 10.1007/BF02987181. Med Oncol Tumor Pharmacother. 1991. PMID: 1803182 Review.
-
The clinical significance of HAMA in patients treated with mouse monoclonal antibodies.Cell Biophys. 1992 Aug-Dec;21(1-3):153-65. doi: 10.1007/BF02789485. Cell Biophys. 1992. PMID: 1285327
-
Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies.Cancer Immunol Immunother. 2006 Dec;55(12):1451-8. doi: 10.1007/s00262-006-0148-4. Epub 2006 Feb 22. Cancer Immunol Immunother. 2006. PMID: 16496145 Free PMC article. Clinical Trial.
-
Monoclonal antibodies as effective therapeutic agents for solid tumors.Cancer Sci. 2004 Aug;95(8):621-5. doi: 10.1111/j.1349-7006.2004.tb03319.x. Cancer Sci. 2004. PMID: 15298722 Free PMC article. Review.
-
Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients.Proc Natl Acad Sci U S A. 1995 May 23;92(11):4773-7. doi: 10.1073/pnas.92.11.4773. Proc Natl Acad Sci U S A. 1995. PMID: 7539133 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials